The challenge of resource allocation for UAV swarms in dynamic and uncertain electromagnetic environments has been ...

Our goal with CosmeticAI™ was to make cosmetic ingredient development predictable rather than exploratory” — Dr. Lurong Pan, CEO of Ainnocence SAN FRANSICO, CA, UNITED STATES, January 1, 2026 ...

In an RL-based control system, the turbine (or wind farm) controller is realized as an agent that observes the state of the ...

In the race against the "Carbon Cliff", AI is becoming an essential tool for balancing the economic equation. AI integration ...

Traditional VR instruction often places students directly into immersive experiences without preparation, resulting in a cognitive “cold start”. To resolve this issue, the first step in the ...

This important study introduces a new biology-informed strategy for deep learning models aiming to predict mutational effects in antibody sequences. It provides solid evidence that separating ...

The Cabinet has officially rescinded its November 2021 directive to dissolve the High Health Council (HHC). The move, announced during Sunday’s session, effectively halts the legislative process to ...

GreenBanana SEO released an in-depth analysis examining how Gemini 3 and a new reasoning layer referred to as “Deep Think” may be changing the mechanics of Google Search, particularly within AI ...

EMERALDWISDOM Trading Center indicated that the release schedule for the new mobile application will be aligned with the platform’s overall development progress, with the current plan targeting early ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical trial of EDG-7500, a novel oral, selective, cardiac sarcomere modulator, ...

If there’s one theme that defines AI in 2025, it’s acceleration. In fact, the pace of advancement hasn’t just increased, but grown exponentially. This year, the industry saw tasks become possible that ...

Edgewise announces completion of EDG-7500 CIRRUS-HCM phase 2 parts B & C and favourable interim safety results from the ongoing part D study in hypertrophic cardiomyopathy ...